bullish

Innovent Biologics Inc

Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”

After continuous pullback, investors may lose interest in Innovent. However, it still has investment value based on pipeline, resources, R&D and technology platforms.It could be the one that wins out.

Equity Bottom-Up
225 Views, 04 Apr 2022 07:57
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • China Healthcare Weekly (Apr.8)-Surgical Robots Pricing Rules,America COMPETES Act,COVID-19 Sequelae
    10 Apr 2022
  • Medlive Technology (2192.HK) - The Logic Has Shaken
    07 Apr 2022
  • JD Health (6618.HK) 2021 Results - The Logic and the Outlook
    06 Apr 2022
  • Innovent Biologics Inc (1801.HK) - Capable of Surviving “this Winter”
    04 Apr 2022
  • BeiGene Ltd (6160.HK/688235.CH) - There Is No Way to Retreat
    08 Mar 2022
  • Interpretation of The "14th Five-Year Plan" For the Development of China Pharmaceutical Industry
    09 Feb 2022
  • Shanghai MicroPort MedBot Group (2252.HK) - Optimistic About the Outlook
    08 Feb 2022
  • Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?
    14 Dec 2021
  • Innovent Biologics (1801.HK) - The Strength and the Concerns
    31 Aug 2021
x